The recent approval of Revolution Medicines’ RAS inhibitor for advanced pancreatic cancer marks a significant milestone in oncology, validating the RAS pathway as a viable therapeutic target. Verastem Oncology CEO Dan Paterson and Chief Scientific Officer Jonathan Pachter emphasize that while this breakthrough offers a crucial leap forward for patients, the field must now prioritize next-generation agents that improve quality of life and overcome resistance mechanisms. Verastem’s strategy focuses on highly selective KRAS G12D inhibition, utilizing compounds like VS-7375 to achieve superior potency and dose-proportional exposure without the toxicities associated with pan-RAS inhibitors. By combining these selective agents with downstream pathway inhibitors and stromal-targeting therapies, the company aims to extend survival beyond the incremental gains
Sign in to continue reading, translating and more.
Open full episode in Podwise